Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa and Saval Ink Licensing Deal for Clobetasol Eye Therapy Post-Surgery
Details : Under the licensing agreement, Saval will holds the right to commercilaize APP13007 (clobetasol propionate). It is being marketed for the treatment of post-operative inflammation and pain.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
April 25, 2025
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
